Report Store

The Report Store is a repository of research reports that are available for online purchase. Each provides an in-depth analysis of a single product or class of products in development within the pharmaceutical, biotechnology, device or diagnostics industries. The goal is to provide actionable insights that enable smart investment decisions around emerging product opportunities. Typically, the reports address:

The scientific and medical rationale for use in the target indication
The strength of available human efficacy and safety data, including the probability of late-phase trial success
Regulatory (eg, FDA) concerns and their likely impact on approval and labeling
Commercial opportunities, including an assessment of the competitive landscape and reimbursement issues.

Sort by

Micromet's blinatumomab: a first-in-class bispecific antibody

A review of the blinatumomab program, the regulatory path to approval and its commercial prospects in acute lymphoblastic leukemia as well as in B-cell NHL, a large opportunity where blinatumomab may face much different challenges. Learn More

GTx's Capesaris - A novel medical castration method

This report explores the risk/benefit profile of Capesaris, as well as the probability of phase III success, the regulatory path to approval, and the market into which it will launch, if successful.
Learn More

Lexicon's LX-4211 - a novel mechanism to treat diabetes

The prospects for LX-4211 and implications of its novel mechanism of action. A review of BMS/AZN’s dapagliflozin program - a bellwether for LX-4211 and the SGLT class.
Learn More

Arqule's tivantinib for NSCLC

This report reviews tivantinib’s pre-clinical and clinical evidence of activity, and the likelihood that it will succeed in late stage development. The report also discusses regulatory considerations, competition and differentiation from other c-MET inhibitors, as well as commercial prospects should tivantinib be approved.

Learn More

Vical's Allovectin - Advancing immunotherapy for metastatic melanoma

This report reviews the evidence for and against Allovectin-7, the odds for success in phase III, potential regulatory risks, and the commercial opportunity in metastatic melanoma for another immunotherapy. Learn More

Cubist's CXA-201 - A novel antibiotic for Gram-negative infections

This report reviews CXA-201’s clinical profile and potential, emerging competition, as well as the market opportunity and commercial prospects for this new antibiotic in the empirical Gram negative treatment setting.
Learn More

Merck KGaA and Oncothyreon's Stimuvax - A Therapeutic Vaccine for Lung Cancer

This report discusses the likelihood of Stimuvax’s success in phase III. Learn More

GTX's Ostarine for cancer cachexia - a debilitating condition in need of therapy

This report explores the strengths and weaknesses of the Ostarine phase II data, the probability of phase III success, regulatory precedents as well as the market for therapies that target cancer cachexia. Learn More

AVEO Pharmaceuticals’ and Astellas Pharma’s Tivozanib - Can this angiogenesis inhibitor distinguish itself from the field?

A review of the available clinical evidence for tivozanib, the odds for success in the pivotal phase III study, and tivozanib's long-term commercial potential as a member of a validated but increasingly crowded class of drugs.
Learn More

NuPathe’s Zelrix: The First Transdermal Sumatriptan Patch

A review of Zelrix's clinical data, its performance relative to other sumatriptan and triptan formulations, the market opportunity for non-oral triptans as well as the key regulatory risk ahead of the August 29th FDA decision date. Learn More